Leveraging Advanced Omics to Uncover Fibrotic Pathomechanisms & Identify Novel Approaches, Evaluate Biomarker Strategy, & Assess Antifibrotics in an Evolving Landscape to Cement Candidate Confidence
Since Madrigal’s Resmetirom secured the first-ever MASH approval in 2024, 2025 went on to deliver a wave of positive antifibrotic advances. United Therapeutics’ Phase 3 win, the FDA’s review of non-invasive endpoints for MASH, Boehringer’s Phase 3 IPF readout, Stanford’s TGF-β breakthroughs in cardiovascular fibrosis, and more than $3B in deals from Lilly and GSK collectively underscored how critical it had become for developers to demonstrate true differentiation-whether through novel targets, innovative biomarker strategies, or pan-fibrotic mechanisms.
These shared challenges were tackled head-on by 80+ leaders from Pfizer, Novartis, Gilead Sciences, and pioneering biotechs at the 9th Antifibrotic Drug Development Summit - he only cross-fibrosis industry meeting uniting discovery through Phase 2 across IPF, MASH, kidney, cardiac, and systemic sclerosis fibrosis.
Download the 2025 Full Event Guide:
- 80+ industry leaders from top pharma, biotech, and academic organisations
- Actionable strategies across IPF, MASH, kidney, cardiac, and gut fibrosis, all in one place
- Exclusive data from recent approvals and Phase 2 successes
- Cutting-edge science including spatial omics, ADCs, and collagen-targeted PET imaging with pioneers
- 8+ hours of tailored networking opportunities
World-Class Speaker Faculty Included:
Kevin Hart
Associate Research Fellow, Scientific Director, Fibrosis Exploratory Biology and Drug Discovery Group
Pfizer
Professor Ardeshir Bayat
Director, Medical Research Council Laboratory, Division of Dermatology
University of Cape Town
“This conference allowed me to get up to date with the large (and growing) amount of effort in the field of fibrosis. There's no other way to get so much information in 2-3 days. Very informative.”
Neuraly
"Very dynamic interactions and vibrant discussions excellent with experts from the field."
Development Center for Biotechnology
"Excellently organized, the workshops and conference went smoothly and offered ample opportunity to get in contact with colleagues and for networking; it is not a question of one single highlight, the overall concept worked out nicely."
Vivoryon Therapeutics
Our 2025 Partners:
